Assessing Off-Target Activity in Preclinical CRISPR Gene Editing

Lee este artículo en voz alta

Enciende el micrófono y lee a tu ritmo. Las palabras se iluminan sobre la marcha y nadie te detiene por un error.

Tu audio nunca llega a MovaReader: lo reconoce tu navegador. Política de Privacidad

Inicia sesión para guardar esta sesión en tu historial de lectura.

Assessing Off-Target Activity in Preclinical CRISPR Gene Editing

The therapeutic deployment of programmable endonucleases, particularly the CRISPR-Cas9 system derived from Streptococcus pyogenes, has revolutionized translational genetics, yet evaluating genomic precision requires rigorous epistemic caution. While standard assays demonstrate that guide RNAs direct the Cas9 endonuclease to cleave targeted loci adjacent to protospacer adjacent motifs, unintended double-strand breaks can occur at non-target sites displaying partial sequence homology. Preclinical evaluations often rely on cell-based selection assays such as GUIDE-seq or in vitro digestion methods like CIRCLE-seq to detect potential off-target cuts. However, molecular geneticists tend to emphasize that cell-free and immortalized cell-line models do not fully mirror chromatin accessibility within primary human tissues.

The biological consequences of off-target cleavage appear to depend heavily on cellular context and repair pathway dynamics. Non-homologous end